Unicycive Therapeutics (NASDAQ:UNCY) Earns “Speculative Buy” Rating from Benchmark

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “speculative buy” rating reiterated by Benchmark in a note issued to investors on Friday,Benzinga reports. They presently have a $3.00 target price on the stock. Benchmark’s target price suggests a potential upside of 460.75% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of Unicycive Therapeutics in a report on Tuesday, November 12th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Unicycive Therapeutics presently has a consensus rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Stock Up 1.4 %

Unicycive Therapeutics stock opened at $0.54 on Friday. The stock has a market cap of $55.53 million, a PE ratio of -0.55 and a beta of 2.29. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.82. The business’s 50-day moving average price is $0.44 and its two-hundred day moving average price is $0.53.

Hedge Funds Weigh In On Unicycive Therapeutics

Several large investors have recently bought and sold shares of UNCY. XTX Topco Ltd bought a new stake in shares of Unicycive Therapeutics during the third quarter worth about $29,000. Virtu Financial LLC boosted its position in Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after buying an additional 62,881 shares during the period. Bleakley Financial Group LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $33,000. Acuta Capital Partners LLC acquired a new position in Unicycive Therapeutics in the 3rd quarter valued at approximately $807,000. Finally, Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics during the third quarter worth $2,040,000. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.